- Research article
- Open Access
The ORFeome of Staphylococcus aureus v 1.1
- Christina J Brandner†1,
- Richard H Maier†1,
- Daryl S Henderson2,
- Helmut Hintner3,
- Johann W Bauer3 and
- Kamil Önder1, 3Email author
© Brandner et al; licensee BioMed Central Ltd. 2008
- Received: 14 March 2008
- Accepted: 07 July 2008
- Published: 07 July 2008
The bacterium Staphylococcus aureus causes significant morbidity and mortality in humans, primarily due to the emergence of strains that are resistant to antibiotics – notably methicillin-resistant S. aureus (MRSA) isolates. Development of effective strategies for the control and treatment of MRSA infections may best be achieved through 'omics' approaches, which first requires cloning the entire set of S. aureus' protein-encoding open reading frames (ORFs), or ORFeome.
The complete genome sequence of S. aureus strain Mu50 has 2697 predicted protein-coding ORFs. Based on the sequence of this strain we designed PCR primers to construct from an S. aureus (non-MRSA) clinical isolate an ORFeome library that contains 2562 unique Gateway® entry clones (95% coverage), each corresponding to a defined ORF. The high quality of the ORFeome library was verified by DNA sequencing and PCR amplification, and its functionality was demonstrated by expressing recombinant proteins and observing protein interactions in a yeast 2-hybrid homodimerization screen.
This first ORFeome library for S. aureus provides an essential new tool for investigating the systems biology of this important pathogen.
- Recombinant Protein Production
- Destination Vector
- Francisella Tularensis
- Entry Clone
- Brucella Melitensis
The number of completely sequenced bacterial genomes, including those of many pathogens, now stands at 640 (revised February 25, 2008) . Such an extensive database provides not only the opportunity to define conserved open reading frames (ORFs) through a comparative genomics approach, but also whole-genome sequence information necessary to construct representative libraries of cloned ORFs, or 'ORFeomes', to enable large-scale, high-throughput 'omics' applications. In the case of hospital- and community-associated methicillin-resistant Staphyloccocus aureus (MRSA) strains, which are causing significant morbidity and mortality worldwide [2–7] the availability of an ORFeome should lead to an improved understanding of the molecular networks governing virulence, pathogenesis, and antibiotic resistance for the control and treatment of S. aureus infection [8–11].
The complete genome sequence of S. aureus strain Mu50  encodes 2697 protein-coding ORFs (gi|47208328|dbj|BA000017.4| ). The massive undertaking to clone ORFs by the thousands cannot be easily achieved by conventional methods using restriction endonucleases. Therefore, we have used the Gateway® site-specific recombinational cloning system  to construct an S. aureus ORFeome library of 2562 unique ORFs (95% coverage) in 'entry' vectors. Such entry vectors permit ORFs to be easily shuttled into other vector types; for example, into protein expression vectors to investigate protein-protein interactions by the yeast 2-hybrid (Y2H) assay . We verified the quality of our S. aureus ORFeome library by PCR amplification and DNA sequencing. To demonstrate its functionality, we tested the production of His-tagged and GST-tagged recombinant proteins in E. coli. Additionally, we performed a Y2H analysis of 150 randomly chosen S. aureus ORFs to test for protein homodimerization, a property which is necessary for the correct functioning of many proteins.
Our repository of S. aureus ORFs offers a highly flexible platform with which to undertake high-throughput genomic and proteomic studies of S. aureus and MRSA infection, including the molecular mechanisms involved in transmission, virulence, immune-escape, and antibiotic resistance.
In addition to a 20- to 30-nucleotide-long ORF-specific sequence, each PCR primer was designed to generate a Gateway®-compatible attB1 (forward primer) or attB2 (reverse primer) recombination site [13, 15] flanking the amplified ORF [see Additional file 2]. Full-length attB sites at the 5' and 3'ends were generated using secondary universal adapter primers in the same PCR. A one-step adapter PCR method was used, instead of the common two-step adapter PCR procedure, to reduce the required cloning steps [see Additional file 2]. To allow for the production of C-terminal fusion proteins, which can be expressed from appropriate destination vectors, the stop codons of each ORF were omitted in the reverse primers. Shine-Dalgarno (5'-GAAGGAGATA-3') and Kozak (5'-ACCATG-3') consensus sequences were incorporated into the forward primers such that the ATG in the Kozak sequence is in frame with the attB1 site, thus allowing N-terminal fusion proteins to be produced from destination vectors that contain N-terminal tags.
Gateway® recombinational cloning
The PCR products were inserted into the Gateway®-compatible vector pDONR™/Zeo (Invitrogen) by BP-cloning. The products resulting from site-specific recombination were transformed into E. coli. A portion of the cells was plated on solid medium containing Zeocin™, and the remainder was used to inoculate liquid medium containing Zeocin™ to generate bacterial stocks of pooled entry clones for long-term freezer storage. On solid medium, ~90% of the plates yielded at least 50 colonies; lower numbers were obtained with inserts >3 kb. A single colony from each plate was tested in a colony-PCR with pDONR™/Zeo-specific primers. The resulting PCR products were detected by gel electrophoresis and ethidium bromide staining. Transformants which had an insert of the expected size were picked and grown in liquid medium containing Zeocin™ to generate bacterial glycerol stocks for long-term freezer storage. By this approach we obtained 1753 transformants carrying the correct insert, which represents 65% of the 2697 predicted ORFs. Using both the positive single-colony glycerol stocks to inoculate liquid medium containing Zeocin™ and the liquid glycerol stocks for those ORFs for which no positive single-colony isolate was obtained, cultures were grown in 96-well plates and plasmid DNAs were prepared and used for PCR. For 2562 (95%) samples, an insert of the size expected for the ORF was observed. The remaining 5% yielded a PCR product of ~300 bp, derived from empty pDONR™/Zeo vector. In light of this result, we expect that additional positive single transformants may be present in the liquid glycerol stocks. The single-colony glycerol stocks, the glycerol stocks of the pooled transformants, and the purified plasmid clones together constitute the ORFeome of S. aureus.
Validation of entry clones by DNA sequencing
To verify that the inserted ORFs are in the correct reading frame and indeed correspond to the assigned identity, we took a random sample of 300 plasmid preparations and subjected them to sequencing with a pDONR™/Zeo-specific forward primer. All 300 samples were found to be correctly inserted, and a BLAST search of each sequence against the S. aureus Mu50 genome (NCBI Refseq: NC_002758) confirmed the identity of each ORF.
Validation of entry clones by recombinant protein production
Yeast two-hybrid homodimerization screen
Twenty-two newly described S. aureus homodimers listed by protein size.
Putative uncharacterized protein
50S ribosomal protein L4
Similar to vraD protein
Ferrichrome transport ATP-binding protein
50S ribosomal protein L2
Similar to NADH-dependent dehydrogenase
Chorismate mutase homolog
Signal recognition particle
Similar to ATPase, AAA family
Transcription termination factor Rho
Putative 2-methylthioadenine synthetase
Glutamyl-tRNA(Gln) amidotransferase subunit A
Probable DEAD-box ATP-dependent RNA helicase
Oligopeptide transport ATP-binding protein
60 kDa chaperonin
Fructose specific permease
Putative uncharacterized protein
ATP-dependent DNA helicase pcrA
The ORFeome of S. aureus that we constructed in this work consists of 1753 ORFs maintained as homogeneous plasmid DNAs purified from single colonies plus 809 ORFs purified from separate 'pools' of entry clones. These 2562 cloned ORFs represent 95% of the S. aureus (Mu50) ORFeome, a proportion of coverage similar to those reported for the ORFeomes of three other bacterial pathogens, Brucella melitensis , Treponema pallidum , and Francisella tularensis . PCR amplification of the ORFs produced products not only of the expected size, but also shorter ones, which were probably primer dimers . Although we did not purify the PCR products as in other ORFeome projects , enough material was produced for individual BP reactions, all of which resulted in colonies after transformation. Testing of the effectiveness of both purified and unpurified PCR products in BP reactions showed that cloning could be achieved to the same extent with both types of PCR products. To minimize the occurrence of PCR-induced mutations, we optimized the PCR conditions, used a proofreading-capable DNA polymerase, and kept the number of amplification cycles low.
Entry clones are the basis for further experiments using recombinational cloning, including genome-wide protein-protein interaction (PPI) analysis, protein expression, and protein localization studies [22–26]. The single entry clones are of higher quality than the pools of entry clones because they are homogeneous, and LR reactions performed subsequently with the pure clones will be more efficient. However, for reasons of economy and because of time constraints, it was not possible to screen every colony to obtain a pure isolate of the appropriate ORF-containing entry clone. When the first colony-PCR failed to produce the anticipated ORF, we screened the remaining pool of colonies to identify the presence of the expected entry clone. We failed to produce PCR products for 135 ORFs. This could be due to possible errors in annotation of the Mu50 genome or, more likely, because of nucleotide differences between our clinical S. aureus isolate and the sequenced Mu50 genome or for technical reasons related to primer design and effectiveness specific to each missing ORF.
Different strains of S. aureus can exhibit important differences in gene content owing to the presence/absence of plasmids and/or mobile elements integrated into the chromosome [e.g., staphylococcal cassette chromosome (SSC) elements, prophage], usually at specific loci termed "genomic islands" . Such factors are important determinants of MRSA virulence and drug resistance, so that an ideal ORFeome would include ORFs for these genes in addition to the bacterial core ORFs. Our ORFeome is certainly incomplete in this regard, because it is a composite of only two S. aureus strains; however, ORFs for virulence and resistance factors of interest could easily be added to the ORFeome as the resource is further characterized and developed.
We assessed the quality of the ORFeome by PCR and agarose gel-electrophoresis of the PCR-products for all the entry clones obtained. Sequencing a sample of 300 PCR products confirmed the identity of the entry clones. Functional validation was done by recombinant protein production and PPI analysis using the Y2H system. In addition to identifying 22 new homodimeric interactions, the experiments also showed the functionality of the ORFeome and its suitability for further applications, including automated high-throughput protein purification or ORFeome-wide PPI analysis. Indeed, generation of an S. aureus intrapathogen 'interactome' is conceivable through ORFeome-wide PPI screening of 3.3 million (2562 × 2562/2) protein-protein interactions by automated procedures. Likewise, a system-wide screen for host-pathogen PPIs could be conducted by screening against other available ORFeomes, e.g. the human ORFeome , which would produce a detailed description of the host-pathogen interface at the molecular level, leading to improved understanding of S. aureus pathogenesis in humans.
Production of recombinant proteins in the present system is achieved with the two well-known protein fusion tags, 6 × His and GST. These tags could be used for further protein purification or affinity studies such as GST Pull-Down  for validation of protein-protein interactions. We successfully produced fusion proteins with both types of tags, although the GST-tagged proteins were more strongly expressed on average than the His-tagged ones in our experiments. His-tagged proteins could not be detected in three out of 20 experiments by Western blotting, due to high background staining caused by the His-specific antibody used or because of low expression rates, or both. Although, we loaded equal amounts of total E. coli protein lysates on protein gels, the intensity of the expressed proteins varied because of degradation in the crude cell lysates. It is interesting to note the presence in some experiments of a second band double the size of the expected molecular weight, suggesting homodimerization, although it is unlikely that dimerization would occur under the denaturation conditions used.
We tested 150 proteins for homodimerization using the Y2H-system and found a total of 22 such interactions (Table 1) after ruling out 37 autoactivators. All Y2H-experiments, including the autoactivator tests, were performed in triplicate, and each PPI was reproducible by independent analysis. It is important to stress that even in the cases of autoactivation, an ORF had to have been expressed in the yeast reporter strain, which again demonstrates the functionality of the ORFeome. The 22 homodimers observed here imply that at least ~15% (22 of 150) of the tested proteins can undergo homodimerization, consistent with the levels found in previous large-scale studies (2–20%) of different organisms [S. cerevisiae 3.6%, C. elegans 2.8%, D. melanogaster 2.2%, and H. sapiens 19.6% ; 143 homodimers among 1546 PPIs (9.25%, Y2H-dataset) in H. sapiens ; 33 homodimers in 1301 human PPIs (2.5%) . Moreover, in the literature we found reports of biochemical and/or structural evidence for homodimerization among homologs (Interologs) of 6 of our 22 dimer-forming proteins (Table 1). For example, RNase III, the product of the SAV1233 clone, is a homodimer in numerous species . In S. aureus, RNase III is an essential regulator of expression of the spa gene, which encodes the virulence factor Staphylococcal protein A.
The cloning of 95% of the S. aureus ORFeome was achieved, and a random sampling of ORF-containing plasmid vectors showed the ORFs to be functional in two different downstream applications: recombinant protein production in E. coli and a protein interaction assay (Y2H). The availability of the S. aureus ORFeome with appropriate Gateway®-compatible destination vectors offers many possibilities for proteome-wide studies of such medically important phenomena as virulence and antibiotic resistance in a high-throughput manner. This first version of the S. aureus ORFeome can be extended in future work by addition of the missing ORFs.
The DNA sequence of S. aureus strain Mu50 was obtained from the NCBI Genome Database (NCBI; Refseq: NC_002758). Primary gene-specific forward primers were designed by adding the sequence 5'-AAAAAGCAGGCTTGGAAGGAGATAGAACCATG-3' to the 5' end of the first 20 to 30 nucleotides of each ORF. Gene-specific reverse primers were constructed by adding the nucleotides 5'-GTACAAGAAAGCTGGGTA-3' to the 5' end of the last 20 to 30 nucleotides of the complementary strand of the ORF. The gene-specific parts of the primary forward and reverse primers were chosen to give a similar annealing temperature during the PCR, between 40–60°C. The 2697 primer pairs were obtained from Illumina Inc. in a 96-well format.
Isolation and preparation of S. aureus genomic DNA
Genomic DNA of S. aureus was prepared from a fresh overnight culture of a clinical isolate of S. aureus (non-MRSA; the strain is sensitive to ampicillin) using the GenElute™ Bacterial Genomic DNA Kit (Sigma-Aldrich). This isolate was originally identified as S. aureus by standard microbiological procedures in a hospital microbiology laboratory (University Hospital Salzburg). After cell harvesting, the pellet was resuspended in resuspension solution containing 3125 U/μl lysozyme and 62.5 U/ml lysostaphin and further prepared and purified according to the product protocol manual. The resulting genomic DNA had a concentration of 200 ng/μl and a 260/280 absorbance ratio of 1.85.
PCR amplification of the ORFs
Each of the 2697 PCRs were performed in 96-well plates containing 50-μl assay volumes consisting of 1.25 U Platinum Pfx polymerase (Invitrogen), 1 mM MgSO4, dNTP mix (0.3 mM each), primary forward and reverse primers (0.1 μM each), secondary adapter forward and reverse primers (0.4 μM each), 10× Pfx amplification buffer (5 μl) and S. aureus genomic DNA (200 ng). The sequence of the secondary forward adapter primer is 5'-GGGGACAAGTTTGTACAAAAAAGCAGGCTTG-3' and that of the secondary reverse adapter primer is 5'-GGGGACCACTTTGTACAAGAAAGCTGGGTA-3'. After the first few cycles, enough DNA template was produced by the primary forward and reverse primers to enable the secondary adapter primers to bind and extend the first PCR products to generate the full-length attB1 and attB2 sites flanking the ORFs. All 4 primers were used together in the same PCR. The 25 PCR cycles (94°C for 30 s, 48°C for 30 s, and 72°C for 1 min/kb) were preceded by heating to 94°C for 5 min and were followed by a 7-min incubation at 72°C. PCR products were used immediately without purification and then stored at -20°C.
attB × attP recombination reactions – BP reactions
The Gateway®-compatible amplified ORFs were recombined into the vector pDONR™/Zeo (Invitrogen) by using the BP Clonase™ II Enzyme Mix (Invitrogen). In 96-well plates, samples containing 2 μl unpurified PCR product, 1 μl BP Clonase™ II Enzyme Mix, 150 ng pDONR™/Zeo plasmid and TE buffer, pH 8.0, up to 10 μl were incubated overnight at 25°C. After adding 1 μg proteinase K (Invitrogen) and incubating at 37°C for 30 minutes, the BP reactions were directly used for bacterial transformation. The reactions were stored at -20°C.
A 3 μl aliquot from each of the 2697 BP reactions was added to One Shot® TOP10 chemically competent E. coli using the manufacturer's protocol and 96-well plates. After heat-shock at 42°C for 30 s, 50 μl of SOC medium (Invitrogen) was added to the transformation reactions and the samples were incubated 1 h at 37°C. After the incubation, 20 μl of each sample were plated onto low-salt LB solid medium containing 80 μg/ml Zeocin™ (Invitrogen) and incubated overnight at 37°C to produce single colonies. The remainder of the transformation reaction was used to inoculate 150 μl of low-salt LB liquid medium containing 80 μg/ml Zeocin™. These cultures were also incubated at 37°C overnight to generate transformants for long-term storage by adding glycerol and freezing at -80°C.
Colony PCR of bacterial clones
A single colony from each transformation reaction was analyzed by PCR to verify the correct size of the inserted ORF. The 2697 PCRs were performed in 96-well plates containing 50-μl samples with 2.5 U BioThermRed™ Polymerase (Genxpress), pDONR™/Zeo-specific forward primer (5'-GTAAAACGACGGCCAG-3') and reverse primer (5'-CAGGAAACAGCTATGAC-3') (0.3 μM each), dNTP mix (0.2 mM each) and 10× BioTherm™ reaction buffer (5 μl). Colonies were picked with a sterile pipet tip and transferred to the wells of the 96-well plate. The 45 PCR cycles (94°C for 30 s, 55°C for 30 s, and 72°C for 1 min/kb) were preceded by heating to 94°C for 5 min and followed by a 7-min incubation at 72°C. The sizes of the PCR products were determined by agarose gel electrophoresis and ethidium bromide staining. Entry clones with inserts having the expected size were inoculated in 150 μl low-salt LB liquid medium containing 80 μg/ml Zeocin™ and incubated overnight at 37°C to generate glycerol long-term frozen stocks. In cases where the PCR failed to verify a positive colony, 'pooled' entry clones were analyzed. An aliquot of the entire transformation reaction was cultured in liquid LB medium overnight at 37°C. The entire overnight culture was subject to plasmid isolation and tested again by PCR. Plasmid preparations from cultures that were positive by PCR indicated the presence of correctly cloned ORFs; at worst, they consisted of a mixed population of cells having empty plasmids and ORF-containing plasmids.
Glycerol long-term frozen stocks and plasmid preparation
Overnight cultures were mixed with glycerol to a final glycerol concentration of 40% for long-term storage at -80°C. One millilitre of low-salt LB liquid medium containing 80 μg/ml Zeocin™ was transferred into 2-ml deep-well plates (Nunc) and inoculated with 2 μl of overnight bacterial culture. After overnight growth at 37°C, plasmids were purified with a ChargeSwitch® NoSpin Plasmid Micro Kit (Invitrogen) in a 96-well plate format.
Sequencing of plasmid DNAs was performed on 300 randomly chosen PCR-positive ORFs. Standard dideoxy sequencing was used [35, 36]. A 10-μl sample containing 5 μl plasmid preparation, the same pDONR™/Zeo forward primer as above (0.32 μM), 2 μl BigDye® Terminator v3.1 Ready Reaction Mix (Applied Biosystems) and 1 μl 5× sequencing buffer was heated to 95°C for 5 min followed by 25 cycles of extension reactions (95°C for 10 s, 50°C for 5 s, and 60°C for 90 s). After precipitating with sodium acetate and absolute ethanol, the redissolved DNA was sequenced with an ABI 3130 Genetic Analyzer Capillary Array (Applied Biosystems).
attL × attR recombination reactions – LR reactions
Entry vectors were set up in LR reactions to recombine the gene of interest into several destination vectors. The destination vectors used were pDEST™15, pDEST™17 (both from Invitrogen), pBD-Gate 2, and pAD-Gate 2 . The two Gate vectors are in-house-generated Gateway®-compatible pGADT7 and pGBKT7 plasmids of the Matchmaker™ GAL4 Two-Hybrid system (Clontech) for yeast two-hybrid analysis. Samples containing 5 μl prepared entry clone, 1 μl LR Clonase™ II Enzyme Mix (Invitrogen), destination vector (150 ng), and TE buffer, pH 8.0, to 10 μl were incubated at 25°C for two hours. After adding 1 μg proteinase K (Invitrogen) and incubating at 37°C for 30 min, the LR reactions were directly used for plasmid transformation into E. coli. The reactions were stored at -20°C. Bacteria were transformed with the LR reactions as described above using the appropriate antibiotic: 100 μg/ml ampicillin for pDEST™15, 17, and pAD-Gate2; and 50 μg/ml kanamycin for pBD-Gate2. Colony PCRs were performed as described above to verify the successful cloning by using vector-specific primers. The expression clones were prepared using a Plasmid Purification NoSpin Plasmid Micro Kit (Invitrogen).
Recombinant protein production
Prepared pDEST™15 and 17 expression vectors, which harbor the desired ORFs, were transformed into chemically competent E. coli BL21(DE3) (Invitrogen) and plated onto LB solid medium containing 100 μg/ml ampicillin. Single colonies from each plate were used to inoculate 3 ml LB liquid medium containing 100 μg/ml ampicillin. Cells were grown at 37°C until the OD600 reached 0.4–0.6, and protein expression was induced by adding IPTG (0.5 mM) and incubating for a further two hours. The cells were lysed and protein expression was shown by SDS-PAGE and Western blot analysis with antibody detection.
Western blot analysis
Proteins were denatured at 95°C for 5 min and separated on a gel (NuPAGE® 10% Bis-Tris Gels (Invitrogen)) at 165 V for 90 min. Buffers used were from Invitrogen (NuPAGE® SDS running buffer, and LDS sample buffer). Proteins were electroblotted onto a Hybond-ECL™ nitrocellulose membrane (Amersham Biosciences) with blotting buffer (3 g Tris, 14.4 g glycine, 200 ml methanol, 10 ml 10% SDS in 1000 ml water, pH 8.4) at 60 V for 1 h.
Membranes were blocked with 5% BSA (Calbiochem, San Diego, CA) in TBS + 0.3% Tween-20® (Sigma-Aldrich) pH 7.4, at room temperature for 1 h, followed by incubation with first antibodies for 1 h. Two 5-min washing steps with TBS were followed by incubation with secondary antibodies for 1 h. After four final washing steps with TBS (10 min each), Western-blue stabilized substrate alkaline phosphatase (Promega) was added. Primary antibodies: Mouse anti-GST (B-14): sc-138 B and mouse anti-His His-probe (H-3): sc-8036 B (Santa Cruz Biotechnology, Santa Cruz, CA); both antibodies are biotin conjugates. Secondary antibodies: anti-mouse IgG – alkaline phosphatase-conjugated (Sigma-Aldrich).
Yeast 2-hybrid analysis – yeast transformation and mating
Prepared expression vectors containing the desired ORFs were transformed into the yeast strains AH109 (Mat a) and Y187 (Mat α) (both Clontech) and first plated on a nutritionally selective plate deficient in tryptophan for pBD-Gate2 transformants and deficient in leucine for pAD-Gate2 transformants. One hundred and fifty baits (pBD-Gate2 Y2H expression vectors harboring the bacterial ORFs) were transformed into AH109 (Mat a) and 150 preys (pAD-Gate2 Y2H expression vectors harboring the bacterial ORFs) were transformed into Y187. After incubation for 5 days at 28°C, up to 5 colonies from each transformation reaction were used to inoculate the corresponding liquid medium and incubated at 28°C until the cultures reached turbidity. Additionally, glycerol stocks were prepared for long-term storage by adding an equal volume of 100% glycerol to the liquid cultures. For the mating procedure, 5 μl of liquid cultures of bait and prey of opposite mating type were brought together on a YPD plate and incubated overnight at 28°C. The next day a small amount of cell material was dissolved in 100 μl of autoclaved distilled water and one-half of each was plated onto a nutritionally selective plate deficient in tryptophan and leucine to test for positive mating and on a nutritionally selective plate deficient in tryptophan, leucine, adenine, and histidine to test for the putative interaction.
We thank Invitrogen for contributing the materials used for cloning the complete S. aureus ORFeome and Dr. Markus Hell for the clinical isolate of S. aureus.
- The NCBI Genome database. [http://www.ncbi.nlm.nih.gov/genomes/static/eub_g.html]
- Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F: Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med. 2008, 148 (4): 249-257.PubMedView ArticleGoogle Scholar
- Zetola N, Francis JS, Nuermberger EL, Bishai WR: Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005, 5 (5): 275-286.PubMedView ArticleGoogle Scholar
- Kollef MH, Micek ST: Methicillin-resistant Staphylococcus aureus: a new community-acquired pathogen?. Curr Opin Infect Dis. 2006, 19 (2): 161-168.PubMedGoogle Scholar
- Wang L, Barrett JF: Control and prevention of MRSA infections. Methods Mol Biol. 2007, 391: 209-225.PubMedView ArticleGoogle Scholar
- Gould IM: MRSA bacteraemia. Int J Antimicrob Agents. 2007, 30 Suppl 1: S66-70.PubMedView ArticleGoogle Scholar
- Griffiths C, Lamagni TL, Crowcroft NS, Duckworth G, Rooney C: Trends in MRSA in England and Wales: analysis of morbidity and mortality data for 1993-2002. Health Stat Q. 2004, 15-22.Google Scholar
- Rachakonda S, Cartee L: Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics. Curr Med Chem. 2004, 11 (6): 775-793.PubMedView ArticleGoogle Scholar
- Wang W, White R, Yuan Z: Proteomic study of peptide deformylase inhibition in Streptococcus pneumoniae and Staphylococcus aureus. Antimicrob Agents Chemother. 2006, 50 (5): 1656-1663.PubMedPubMed CentralView ArticleGoogle Scholar
- Walsh C: Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000, 406 (6797): 775-781.PubMedView ArticleGoogle Scholar
- Mills SD: The role of genomics in antimicrobial discovery. J Antimicrob Chemother. 2003, 51 (4): 749-752.PubMedView ArticleGoogle Scholar
- Kuroda M, Ohta T, Uchiyama I, Baba T, Yuzawa H, Kobayashi I, Cui L, Oguchi A, Aoki K, Nagai Y, Lian J, Ito T, Kanamori M, Matsumaru H, Maruyama A, Murakami H, Hosoyama A, Mizutani-Ui Y, Takahashi NK, Sawano T, Inoue R, Kaito C, Sekimizu K, Hirakawa H, Kuhara S, Goto S, Yabuzaki J, Kanehisa M, Yamashita A, Oshima K, Furuya K, Yoshino C, Shiba T, Hattori M, Ogasawara N, Hayashi H, Hiramatsu K: Whole genome sequencing of meticillin-resistant Staphylococcus aureus. Lancet. 2001, 357 (9264): 1225-1240.PubMedView ArticleGoogle Scholar
- Walhout AJ, Temple GF, Brasch MA, Hartley JL, Lorson MA, van den Heuvel S, Vidal M: GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol. 2000, 328: 575-592.PubMedView ArticleGoogle Scholar
- Fields S, Song O: A novel genetic system to detect protein-protein interactions. Nature. 1989, 340 (6230): 245-246.PubMedView ArticleGoogle Scholar
- Hartley JL, Temple GF, Brasch MA: DNA cloning using in vitro site-specific recombination. Genome Res. 2000, 10 (11): 1788-1795.PubMedPubMed CentralView ArticleGoogle Scholar
- Furuta E, Yamamoto K, Tatebe D, Watabe K, Kitayama T, Utsumi R: Targeting protein homodimerization: a novel drug discovery system. FEBS Lett. 2005, 579 (10): 2065-2070.PubMedView ArticleGoogle Scholar
- Dricot A, Rual JF, Lamesch P, Bertin N, Dupuy D, Hao T, Lambert C, Hallez R, Delroisse JM, Vandenhaute J, Lopez-Goni I, Moriyon I, Garcia-Lobo JM, Sangari FJ, Macmillan AP, Cutler SJ, Whatmore AM, Bozak S, Sequerra R, Doucette-Stamm L, Vidal M, Hill DE, Letesson JJ, De Bolle X: Generation of the Brucella melitensis ORFeome version 1.1. Genome Res. 2004, 14 (10B): 2201-2206.PubMedPubMed CentralView ArticleGoogle Scholar
- McKevitt M, Patel K, Smajs D, Marsh M, McLoughlin M, Norris SJ, Weinstock GM, Palzkill T: Systematic cloning of Treponema pallidum open reading frames for protein expression and antigen discovery. Genome Res. 2003, 13 (7): 1665-1674.PubMedPubMed CentralView ArticleGoogle Scholar
- Murthy T, Rolfs A, Hu Y, Shi Z, Raphael J, Moreira D, Kelley F, McCarron S, Jepson D, Taycher E, Zuo D, Mohr SE, Fernandez M, Brizuela L, Labaer J: A full-genomic sequence-verified protein-coding gene collection for Francisella tularensis. PLoS ONE. 2007, 2 (6): e577-PubMedPubMed CentralView ArticleGoogle Scholar
- Schroeder BK, House BL, Mortimer MW, Yurgel SN, Maloney SC, Ward KL, Kahn ML: Development of a functional genomics platform for Sinorhizobium meliloti: construction of an ORFeome. Appl Environ Microbiol. 2005, 71 (10): 5858-5864.PubMedPubMed CentralView ArticleGoogle Scholar
- Gong W, Shen YP, Ma LG, Pan Y, Du YL, Wang DH, Yang JY, Hu LD, Liu XF, Dong CX, Ma L, Chen YH, Yang XY, Gao Y, Zhu D, Tan X, Mu JY, Zhang DB, Liu YL, Dinesh-Kumar SP, Li Y, Wang XP, Gu HY, Qu LJ, Bai SN, Lu YT, Li JY, Zhao JD, Zuo J, Huang H, Deng XW, Zhu YX: Genome-wide ORFeome cloning and analysis of Arabidopsis transcription factor genes. Plant Physiol. 2004, 135 (2): 773-782.PubMedPubMed CentralView ArticleGoogle Scholar
- Rual JF, Hill DE, Vidal M: ORFeome projects: gateway between genomics and omics. Curr Opin Chem Biol. 2004, 8 (1): 20-25.PubMedView ArticleGoogle Scholar
- Walhout AJ, Boulton SJ, Vidal M: Yeast two-hybrid systems and protein interaction mapping projects for yeast and worm. Yeast. 2000, 17 (2): 88-94.PubMedPubMed CentralView ArticleGoogle Scholar
- Walhout AJ, Vidal M: Protein interaction maps for model organisms. Nat Rev Mol Cell Biol. 2001, 2 (1): 55-62.PubMedView ArticleGoogle Scholar
- Ziauddin J, Sabatini DM: Microarrays of cells expressing defined cDNAs. Nature. 2001, 411 (6833): 107-110.PubMedView ArticleGoogle Scholar
- Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, Lan N, Jansen R, Bidlingmaier S, Houfek T, Mitchell T, Miller P, Dean RA, Gerstein M, Snyder M: Global analysis of protein activities using proteome chips. Science. 2001, 293 (5537): 2101-2105.PubMedView ArticleGoogle Scholar
- Baba T, Takeuchi F, Kuroda M, Yuzawa H, Aoki K, Oguchi A, Nagai Y, Iwama N, Asano K, Naimi T, Kuroda H, Cui L, Yamamoto K, Hiramatsu K: Genome and virulence determinants of high virulence community-acquired MRSA. Lancet. 2002, 359 (9320): 1819-1827.PubMedView ArticleGoogle Scholar
- Lamesch P, Li N, Milstein S, Fan C, Hao T, Szabo G, Hu Z, Venkatesan K, Bethel G, Martin P, Rogers J, Lawlor S, McLaren S, Dricot A, Borick H, Cusick ME, Vandenhaute J, Dunham I, Hill DE, Vidal M: hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics. 2007, 89 (3): 307-315.PubMedPubMed CentralView ArticleGoogle Scholar
- Ren L, Chang E, Makky K, Haas AL, Kaboord B, Walid Qoronfleh M: Glutathione S-transferase pull-down assays using dehydrated immobilized glutathione resin. Anal Biochem. 2003, 322 (2): 164-169.PubMedView ArticleGoogle Scholar
- Ispolatov I, Yuryev A, Mazo I, Maslov S: Binding properties and evolution of homodimers in protein-protein interaction networks. Nucleic Acids Res. 2005, 33 (11): 3629-3635.PubMedPubMed CentralView ArticleGoogle Scholar
- Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP, Vidal M: Towards a proteome-scale map of the human protein-protein interaction network. Nature. 2005, 437 (7062): 1173-1178.PubMedView ArticleGoogle Scholar
- Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, Goehler H, Stroedicke M, Zenkner M, Schoenherr A, Koeppen S, Timm J, Mintzlaff S, Abraham C, Bock N, Kietzmann S, Goedde A, Toksoz E, Droege A, Krobitsch S, Korn B, Birchmeier W, Lehrach H, Wanker EE: A human protein-protein interaction network: a resource for annotating the proteome. Cell. 2005, 122 (6): 957-968.PubMedView ArticleGoogle Scholar
- MacRae IJ, Doudna JA: Ribonuclease revisited: structural insights into ribonuclease III family enzymes. Curr Opin Struct Biol. 2007, 17 (1): 138-145.PubMedView ArticleGoogle Scholar
- Huntzinger E, Boisset S, Saveanu C, Benito Y, Geissmann T, Namane A, Lina G, Etienne J, Ehresmann B, Ehresmann C, Jacquier A, Vandenesch F, Romby P: Staphylococcus aureus RNAIII and the endoribonuclease III coordinately regulate spa gene expression. Embo J. 2005, 24 (4): 824-835.PubMedPubMed CentralView ArticleGoogle Scholar
- Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977, 74 (12): 5463-5467.PubMedPubMed CentralView ArticleGoogle Scholar
- Smith LM, Sanders JZ, Kaiser RJ, Hughes P, Dodd C, Connell CR, Heiner C, Kent SB, Hood LE: Fluorescence detection in automated DNA sequence analysis. Nature. 1986, 321 (6071): 674-679.PubMedView ArticleGoogle Scholar
- Maier RH, Brandner CJ, Hintner H, Bauer JW, Önder K: Construction of a reading-frame-independent yeast two-hybrid vector system for site-specific recombinational cloning and protein interaction screening. Biotechniques.Google Scholar
- Burr B, Walker J, Truffa-Bachi P, Cohen GN: Homoserine kinase from Escherichia coli K12. Eur J Biochem. 1976, 62 (3): 519-526.PubMedView ArticleGoogle Scholar
- Anselme J, Hartlein M: Asparaginyl-tRNA synthetase from Escherichia coli has significant sequence homologies with yeast aspartyl-tRNA synthetase. Gene. 1989, 84 (2): 481-485.PubMedView ArticleGoogle Scholar
- Geiselmann J, Seifried SE, Yager TD, Liang C, von Hippel PH: Physical properties of the Escherichia coli transcription termination factor rho. 2. Quaternary structure of the rho hexamer. Biochemistry. 1992, 31 (1): 121-132.PubMedView ArticleGoogle Scholar
- Hutchinson JP, el-Thaher TS, Miller AD: Refolding and recognition of mitochondrial malate dehydrogenase by Escherichia coli chaperonins cpn 60 (groEL) and cpn10 (groES). Biochem J. 1994, 302 ( Pt 2): 405-410.View ArticleGoogle Scholar
- Maluf NK, Fischer CJ, Lohman TM: A Dimer of Escherichia coli UvrD is the active form of the helicase in vitro. J Mol Biol. 2003, 325 (5): 913-935.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.